Result of AGM

Source: RNS
RNS Number : 2789T
Futura Medical PLC
20 June 2024
 

20 June 2024

Futura Medical plc

("Futura", "the Group" or the "Company")

Result of AGM

 

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, today announces that at its Annual General Meeting, held today at 10:00am BST, the shareholders duly passed all resolutions.

 

The total number of votes received on each resolution were as follows:

 

 



Voting For                       

Voting Against                       



 

Number of votesi

%

Number of votes

%

Total Votes

% ISC

Votes withheldii

Resolution 1

To receive and adopt the annual report and accounts for the financial year ended 31 December 2023

145,896,305

99.50

738,451

0.50

146,634,756

48.57

121,536

Resolution 2

That Roy Davis be and is hereby appointed as a Director of the Company.

146,637,030

99.98

30,544

0.02

146,667,574

48.58

91,718

Resolution 3

To re-elect Angela Hildreth as a Director of the Company, who retires by rotation in accordance with

the Company's articles of association.

146,583,928

99.94

80,896

0.06

146,664,824

48.58

91,468

Resolution 4

To re-appoint Grant Thornton UK LLP as auditor of the Company to hold office until the conclusion of

the next annual general meeting of the Company.

146,559,436

99.95

74,813

0.05

146,634,249

48.57

122,043

Resolution 5

To authorise the Directors to determine the remuneration of Grant Thornton UK LLP as auditor of the

Company

146,544,066

99.95

68,860

0.05

146,612,926

48.56

143,366

Resolution 6

That the Directors are generally and unconditionally authorised for the purposes of section 551

Companies Act 2006 (the "CA 2006") to exercise all the powers of the Company to allot shares in the

Company and to grant rights to subscribe for or to convert any security into shares in the Company.

146,000,585

99.50

735,009

0.50

146,735,594

48.60

20,698

Resolution 7iii

Disapplication of pre-emption rights 

145,446,404

99.13

1,279,733

0.87

146,726,137

48.60

30,155

Resolution 8 iii

Disapplication of pre-emption rights in respect of an additional 20% of the company issued share capital

146,060,258

99.54

669,879

0.46

146,730,137

48.60

26,155

 

Where shareholders appointed the Chairman as their proxy with discretion as to voting, their votes were cast in favour of the resolution

ⁱⁱ A vote withheld is not a vote in law and is not counted towards the votes cast "For" or "Against" a resolution

ⁱⁱⁱ Special Resolution (75% majority required)

The total voting rights of the Company as at 10:00 am on 18 June 2024 (the time by which shareholders wanting to vote at the AGM were required to be entered on the register) was 301,863,641 ordinary shares of 0.2p each. The Company does not hold any shares in treasury.

 

 

 

Contacts:

Futura Medical plc

 

 

 

James Barder

Chief Executive Officer

Angela Hildreth

Finance Director and COO

 

investor.relations@futuramedical.com

+44 (0)1483 685 670

www.futuramedical.com

 

Liberum

Nominated Adviser

and Broker

 

Richard Lindley

Nikhil Varghese

+44 (0)20 3100 2000

 

 

 



Stifel Nicolaus Europe Limited

Joint Broker

 

Alan Selby

Ben Maddison

 

+44 (0)207 710 7600

 

 

 



Alma Strategic Communications

Rebecca Sanders-Hewett

Sam Modlin

Will Ellis Hancock

+44 (0)20 3405 0205

futura@almastrategic.com




 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGURAVRSAUNUAR